Reform and Impact of China's Medical Device Registration System in 2025

Breakthrough and Reconstruction: Deep Reform of China's Medical Device Registration System in 2025 and Industry Insights

As artificial intelligence assisted diagnostic devices begin to enter community hospitals and wearable health monitoring instruments become standard in households, the medical device industry is undergoing unprecedented technological iterations. In this era of innovation explosion, China's medical device registration system has also undergone profound changes. The comprehensive implementation of the new version of the Medical Device Supervision and Administration Regulations in 2024, coupled with the upgraded version of the registrant system that will be implemented in 2025, is reshaping the game rules of the entire industry.




1、 Institutional upgrading: the essential transformation from "threshold" to "track"

The most significant change in the registration system in 2025 is the paradigm shift from "access control" to "full cycle management". The approval deadline for clinical trials has been compressed to 45 working days, and the scope of application of the special approval channel for innovative medical devices has been expanded to Class II devices. These changes not only optimize the process, but also reflect a fundamental shift in regulatory thinking. A certain IVD company in Hangzhou has advanced the launch time of its new product by 11 months through the "research and review linkage" mechanism, vividly demonstrating the value of the new system.




Digital technology is profoundly changing the registration process. The electronic declaration system of the Medical Device Evaluation Center (CMDE) of the National Medical Products Administration has achieved paperless processing of over 95% of materials, and the AI assisted evaluation system can automatically identify 80% of formatting issues. However, it is worth noting that the average time for technical review remains at around 120 days, indicating that substantive review is still an insurmountable "quality red line".




2、 Real world data: a paradigm revolution in clinical evaluation

The most breakthrough change in 2025 lies in the comprehensive application of RWS (Real World Research) data. A domestic heart valve saved 27 million yuan in costs by collecting 3285 clinical usage data instead of traditional clinical trials. But this innovation also brings new challenges: how to ensure data quality? The case of a company in Shenzhen being required to provide additional materials due to incomplete RWS data traceability highlights the importance of data governance.




At the specific implementation level, different types of instruments face different situations:

Imaging diagnostic equipment: DICOM standard data can be directly used for performance validation

Rehabilitation equipment: The usage data generated by the Internet of Things can serve as proof of effectiveness

Implanted devices: strict follow-up combined with traditional clinical trials is still needed




3、 Cross border regulation: Compliance restructuring brought about by globalization

With China's accession to the IMDRF (International Medical Device Regulatory Forum), mutual recognition of review results with the EU MDR and the US FDA will be achieved by 2025. Medtronic's latest approved neurostimulator directly uses overseas clinical data, saving 18 months of time. However, local enterprises such as Mindray Medical still need to invest about 3.5% of their revenue to meet the registration requirements of multiple countries, indicating that the cost of international compliance cannot be ignored.




The pilot project of "registration integration" in the Guangdong Hong Kong Macao Greater Bay Area shows that mutual recognition of standards among the three regions has shortened the product launch cycle by 40%. This regional exploration may become a Chinese solution to address global regulatory fragmentation.




4、 Enterprise response: finding a balance between compliance and innovation

Top enterprises have begun to restructure their research and development systems. The "registration driven research and development" model established by Minimally Invasive Medical has reduced the average registration time of products to 2/3 of competitors. However, startups face a dilemma: the game between first mover advantage and compliance risk. The lesson of a certain AI medical imaging company in Beijing being rejected for registration due to its eagerness to go public shows that grasping the balance point requires professional judgment.




The battle for talent has already begun. The annual salary increase for compound talents who understand both clinical practice and registration is 25%, and data from a headhunter shows that there is a talent gap of over 12000 people in the industry. This structural shortage will continue at least until 2026.




Looking back at the milestone of 2025, China's medical device registration system has evolved from a simple administrative approval to an infrastructure that promotes high-quality development of the industry. The loosening of regulations has released innovative vitality, but the accompanying restructuring of responsibility systems, challenges in data governance, and global compliance requirements are all testing the adaptability of enterprises. The future is here, only by embracing change with a professional attitude can we gain an advantage in the new era of medical devices. This quiet regulatory revolution will eventually translate into safer and more advanced medical solutions in the hands of patients.